Early stage NSCLS patients’ prognostic prediction with multi-information using transformer and graph neural network model
- Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China
- Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, China
- Department of Psychiatry, The Chinese University of Hong Kong, China
- Division of Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, China
Figures
Figure 1
Overall flow of the study in both internal and external data set.
Figure 2
Tumour image processing and feature generation.
(A) Tumour images normalisation, reshaping, and padding to standard sizes, then re-arranged into 2D images. (B) Generating 1D Transformer survival features from pretrained Transformer model.
Figure 3
Population graph building and model prediction pipeline.
(A) Each patient was regarded as a node and the Transformer-generated feature was regarded as node features. (B) Graph edges and the relevant weights were defined by their similarity scores. (C) We …
Figure 4 with 1 supplement
Model performance: (A) ROC-AUC curve on test data and external set for OS and (B) RFS prediction and (C) KM curve on test data set for OS and (D) RFS prediction.
(E) Decision curve on test data set for OS and RFS prediction. KM, Kaplan–Meier; OS, overall survival; RFS, recurrence-free survival; ROC-AUC, area under the receiver operator characteristic curve.
Figure 4—figure supplement 1
Kaplan-Meier survival analysis.
(A) KM curve on external data set for OS and (B) RFS prediction.
Figure 5
Testing set graph analysis.
(A) A visual representation of the whole cohort population graph of 1705 patients. (B) A visual representation of the testing sub-graph of 213 patients. (C) and (D) two sub-graphs containing …
Tables
Table 1
Feature distribution in the total patient cohorts, training and validation cohorts and the test cohorts.
| TRAIN and VAL(n=1492) | TEST(n=213) | EXTERNAL(n=127) | ||||
|---|---|---|---|---|---|---|
| Feature | Content | Mean, SD, 95% CI/Count, % | p | Mean, SD, 95% CI/Count, % | p | |
| Age | Age | 60.6, 8.7, (CI: 60.1, 61.0) | 60.7, 9.5, (CI: 59.4, 62.0) | >0.05 | 68.7, 9.1, (CI: 67.2, 70.1) | <0.01** |
| Sex | Female no. (%); Male no. (%) | 602 (33.3); 890 (66.7) | 93 (33.3); 120 (66.7) | >0.05 | 32 (25.2); 95 (74.8) | <0.01** |
| Resection | Sublobar resection no. (%); Lobectomy no. (%); Bilobectomy no. (%); Pneumonectomy no. (%) | 123 (8.2); 1292 (86.6); 59 (3.95); 18 (1.2) | 23 (10.8); 180 (84.5); 7 (3.3); 3 (1.4) | >0.05 | / | / |
| Histology | Adenocarcinoma no. (%); Squamous Cell Carcinoma no. (%); Others no. (%) | 1072 (71.4); 351 (23.5); 69 (4.6) | 163 (76.5); 40 (18.8); 10 (4.7) | >0.05 | 95 (74.8); 30 (23.6); 2 (1.6) | >0.05 |
| Tumour location | LUL no. (%); LLL no. (%); RUL no. (%); RML no. (%); RLL no. (%) | 384 (25.7); 211 (14.1); 504 (33.8); 146 (9.8); 247 (16.6) | 51 (23.9); 37 (17.4); 79 (37.1); 15 (7.0) 31 (14.6) | >0.05 | 30 (23.6); 22 (17.3); 46 (36.2); 15 (11.8); 14 (11.0). | >0.05 |
| Tumour size | Tumour size | 2.68, 1.38, (CI: 2.61, 2.75) | 2.55, 1.25, (CI: 2.38, 2.71) | >0.05 | / | / |
| pTNM stage | Stage I no. (%); Stage II no. (%); | 1219 (81.7); 273 (18.3) | 179 (84.0); 34 (16.0) | >0.05 | 97 (76.3); 30 (23.7) | <0.01** |
| RFS status | RFS no. (%) | 1089 (73.0) | 154 (72.3) | >0.05 | 75 (59.1) | >0.05 |
| RFS month | RFS month | 57.5, 24.5, (CI: 56.2, 58.7) | 58.4, 23.4, (CI: 55.2, 61.5) | >0.05 | 39.5, 26.9, (CI: 34.8, 44.2) | <0.01** |
| OS status | OS no. (survival %) | 1166 (78.2) | 167 (78.4) | >0.05 | 87 (68.5) | >0.05 |
| OS month | OS month | 62.4, 19.9, (CI: 61.4, 63.4) | 63.4, 18.4, (CI: 60.9, 65.9) | >0.05 | 44.8, 27.8, (CI: 40.9, 50.0) | <0.01** |
Additional files
-
Supplementary file 1
Ethnicity and Smoking information table of the external dataset.
- https://cdn.elifesciences.org/articles/80547/elife-80547-supp1-v1.docx
-
MDAR checklist
- https://cdn.elifesciences.org/articles/80547/elife-80547-mdarchecklist1-v1.pdf
